Vanguard Group Inc. increased its stake in GenMark Diagnostics, Inc. (NASDAQ:GNMK) by 3.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,956,681 shares of the medical equipment provider’s stock after buying an additional 58,691 shares during the period. Vanguard Group Inc. owned 4.16% of GenMark Diagnostics worth $25,084,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of GNMK. Guggenheim Capital LLC increased its stake in shares of GenMark Diagnostics by 0.4% in the fourth quarter. Guggenheim Capital LLC now owns 10,694 shares of the medical equipment provider’s stock worth $131,000 after buying an additional 39 shares during the last quarter. AQR Capital Management LLC acquired a new stake in shares of GenMark Diagnostics during the fourth quarter worth $189,000. Teachers Advisors LLC increased its stake in shares of GenMark Diagnostics by 6.1% in the fourth quarter. Teachers Advisors LLC now owns 98,220 shares of the medical equipment provider’s stock worth $1,202,000 after buying an additional 5,652 shares during the last quarter. Quantitative Systematic Strategies LLC acquired a new stake in shares of GenMark Diagnostics during the first quarter worth $142,000. Finally, Nationwide Fund Advisors increased its stake in shares of GenMark Diagnostics by 3.9% in the first quarter. Nationwide Fund Advisors now owns 25,936 shares of the medical equipment provider’s stock worth $332,000 after buying an additional 981 shares during the last quarter. Hedge funds and other institutional investors own 93.07% of the company’s stock.

Shares of GenMark Diagnostics, Inc. (NASDAQ:GNMK) traded down 2.40% during mid-day trading on Monday, reaching $9.37. The company’s stock had a trading volume of 68,651 shares. GenMark Diagnostics, Inc. has a 12 month low of $8.03 and a 12 month high of $13.67. The company’s 50-day moving average is $11.19 and its 200 day moving average is $12.12. The firm’s market cap is $512.23 million.

GenMark Diagnostics (NASDAQ:GNMK) last issued its quarterly earnings data on Tuesday, August 1st. The medical equipment provider reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.32) by $0.05. The firm had revenue of $12.36 million for the quarter, compared to the consensus estimate of $12.44 million. GenMark Diagnostics had a negative net margin of 111.96% and a negative return on equity of 109.89%. The business’s revenue was down 1.2% on a year-over-year basis. During the same period last year, the company posted ($0.30) earnings per share. On average, equities analysts anticipate that GenMark Diagnostics, Inc. will post ($1.07) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This report was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at https://theolympiareport.com/2017/08/21/vanguard-group-inc-has-25-08-million-stake-in-genmark-diagnostics-inc-gnmk.html.

GNMK has been the subject of a number of recent analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $15.00 price target on shares of GenMark Diagnostics in a report on Sunday, April 23rd. Zacks Investment Research downgraded GenMark Diagnostics from a “buy” rating to a “hold” rating in a report on Wednesday, May 3rd. BTIG Research reiterated a “buy” rating and set a $17.00 price target on shares of GenMark Diagnostics in a report on Wednesday, May 17th. ValuEngine upgraded GenMark Diagnostics from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, Canaccord Genuity reiterated a “buy” rating and set a $17.00 price target on shares of GenMark Diagnostics in a report on Monday, June 12th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $15.80.

GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.

Institutional Ownership by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Ratings for GenMark Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.